Treatments & Therapies
How Long Does SPRAVATO® Take to Work? Tyler, TX Guide
Some patients notice SPRAVATO® effects within days — many see meaningful response by the end of the 4-week induction phase. Here is what the evidence and experience show.
Quick Answer
SPRAVATO® (esketamine) can produce meaningful antidepressant effects faster than traditional oral antidepressants. Some patients report improvement after the first or second session; clinical studies show significant response rates by the end of the four-week induction phase. Response is not guaranteed and varies by individual. East Texas Psychiatry monitors your progress with validated measures throughout treatment.
01What the Clinical Evidence Shows About SPRAVATO® Onset
One of SPRAVATO®'s most clinically significant attributes is its speed of onset relative to traditional antidepressants. Standard SSRIs and SNRIs typically require four to eight weeks of consistent dosing before patients experience their full antidepressant effect. For patients with treatment-resistant depression who have been waiting for relief through multiple medication trials, this timeline compounds an already long history.
SPRAVATO® operates through a different mechanism — NMDA receptor modulation that triggers rapid synaptogenesis — that produces antidepressant effects on a faster timescale. In pivotal clinical trials, statistically significant separation from placebo was observed as early as day four in some study populations.
Specifically, in the TRANSFORM-2 trial (the pivotal TRD trial supporting SPRAVATO®'s FDA approval), the treatment group showed statistically significant improvement in depression scores compared to placebo at day 28 (the end of the four-week induction phase). Some trials also showed significant or near-significant separation at earlier time points — day 15 and day 8.
These are group-level statistics — not every patient responds at the same rate or with the same intensity. But they establish that SPRAVATO® produces meaningful antidepressant effects on a timeline that is genuinely different from what patients who have tried multiple SSRIs or SNRIs have experienced before.
02Week-by-Week: What to Expect During Induction
The four-week induction phase consists of eight sessions — two per week. Here is a realistic picture of what patients typically experience across this phase, based on clinical trial data and clinical practice.
Week 1 (Sessions 1–2): The first session is the most uncertain. Many patients experience the expected acute effects — mild dissociation, possibly dizziness or nausea — and leave feeling somewhat disoriented. Antidepressant effects, if they occur in week one, are often subtle at this stage. Some patients notice a lift in mood within 24–48 hours of their first session; others do not notice anything during the first week.
Week 2 (Sessions 3–4): By the second week, the session experience is more familiar and often more manageable. Some patients begin to notice meaningful changes in mood, energy, or motivation during this week. Others are still waiting for a clear signal.
Week 3 (Sessions 5–6): Week three is often when response becomes more apparent — either as a clear improvement in daily function and mood, or as a signal that response at the standard dose is limited and an adjustment may be warranted. We assess symptoms formally at this stage.
Week 4 (Sessions 7–8): By the end of induction, the clinical picture is usually clear. Patients who are responding well typically report meaningful improvement in depression symptoms, energy, and daily function. At this point, we plan the transition to maintenance.
| Question | What to know |
|---|---|
| First signs of response | Days 2–7 for some patients; not universal in the first week. |
| Common response window | Weeks 2–4 of induction — 8 sessions over 4 weeks. |
| Primary clinical trial endpoint | Day 28 (end of induction) — statistically significant vs. placebo in TRD. |
| What if no response by week 4? | Dose adjustment, session adjustments, or alternative approaches discussed. |
| Maintenance phase | Weekly or biweekly sessions to sustain response after induction. |
| How long maintenance lasts | Varies by patient — months to long-term, evaluated collaboratively. |
03Factors That Influence How Quickly SPRAVATO® Works
Individual variation in SPRAVATO® response is real and clinically significant. Several factors are associated with faster or slower response and with the likelihood of meaningful response at all.
Severity and duration of depression: Patients with longer depression histories and more severe baseline symptoms sometimes require more sessions to see a clear response. This does not mean treatment is failing — it may mean the therapeutic window is longer.
Co-occurring conditions: Anxiety disorders, PTSD, ADHD, and chronic pain can affect baseline mood and complicate the interpretation of early response signals. Treating these conditions alongside SPRAVATO® often produces better and more durable outcomes.
Background antidepressant: SPRAVATO® is typically used alongside a background oral antidepressant. The choice and optimization of that antidepressant can affect the overall therapeutic response.
Session spacing and consistency: Missing sessions during induction may affect the therapeutic trajectory. Completing the full eight-session induction consistently is important for giving the treatment a fair chance.
Psychosocial factors: Ongoing significant stressors — relationship conflict, job loss, housing instability — can moderate SPRAVATO®'s antidepressant effects. These are not reasons to defer treatment, but they are factors that a good care plan addresses explicitly.
04When Response Is Incomplete — What We Do Next
Not every patient has a strong response to SPRAVATO® during the standard induction phase. This is a known clinical reality, and our approach to incomplete response is transparent and structured.
Assessment: We use validated depression rating scales at key points across the induction phase. If scores are not improving meaningfully by week three, we have a conversation about what may be affecting response and what options exist.
Dose adjustment: Esketamine is available in two doses (56 mg and 84 mg). Patients who begin on the lower dose and do not show adequate response may be trialed on the higher dose.
Session frequency: In some cases, extending the induction phase or adjusting session spacing can support a more complete response.
Background medication adjustment: If the oral antidepressant being used alongside SPRAVATO® is not optimized, adjusting it may improve overall response.
Alternative approaches: If SPRAVATO® does not produce adequate response after a thorough trial, we discuss alternatives — including other augmentation strategies, electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), or a referral to a specialized tertiary psychiatric center.
We accept Aetna, Ambetter, Blue Cross Blue Shield, Cigna/Evernorth, Medicare, Optum, UnitedHealthcare, and UMR.
The challenge
Untreated treatment-resistant depression compounds over time — mood, cognition, relationships, and physical health all deteriorate the longer depression persists.
Our approach
East Texas Psychiatry tracks your SPRAVATO® response with validated measures across the full treatment course — making evidence-based adjustments when needed.
The outcome
SPRAVATO® clinical trials showed statistically significant antidepressant effects by day 28 in patients with TRD — a population for whom traditional antidepressants had already failed.
Take the first step
Help starts with one conversation — most new patients are seen within a week.
05Maintenance — Sustaining SPRAVATO® Response Over Time
Achieving a response during induction is the beginning, not the end, of SPRAVATO® treatment planning. Many patients require maintenance sessions to sustain their improvement and prevent relapse back into treatment-resistant depression.
Maintenance sessions typically occur weekly or biweekly after the induction phase. The frequency is adjusted based on your response pattern — some patients maintain well with biweekly sessions, others need weekly to sustain their improvement.
Duration of maintenance varies significantly between patients. Some achieve durable remission after several months of maintenance and successfully taper off SPRAVATO® with the improvement sustained. Others require ongoing maintenance long-term to maintain the therapeutic benefit. This is not a failure — it is the clinical reality for some forms of treatment-resistant depression.
We monitor your symptom trajectory continuously during maintenance using validated measures, not just subjective impression. Objective tracking allows us to detect early signs of symptom return and respond before a full relapse occurs.
ProvidersYour Care Team in Tyler
James Baughman & Antonio Brigham, PMHNP-BC
- James Baughman, PMHNP-BC — co-founder, U.S. Navy veteran, 35+ years of combined clinical experience in psychiatric care.
- Antonio Brigham, PMHNP-BC — co-founder, dual board-certified, holistic approach integrating medication management and evidence-based therapy.
- Karen A. English, PMHNP-BC — child and adolescent psychiatry specialist, serving younger patients and their families under the same roof.
- Together, they have built a practice where board-certified expertise, unhurried evaluations, and coordinated care are the standard — not the exception.
Every provider at East Texas Psychiatry holds board certification in psychiatric-mental health nursing (PMHNP-BC). Care is delivered at our Tyler clinic or by secure telepsychiatry anywhere in Texas. Our team accepts most major insurance plans, including Medicare, Aetna, Blue Cross Blue Shield, Cigna/Evernorth, Optum, UnitedHealthcare, UMR, and Ambetter.
06Tracking Your Progress at East Texas Psychiatry
Knowing whether SPRAVATO® is working requires more than a general sense of how you feel. We use validated, standardized depression rating scales at regular intervals across your treatment — induction and maintenance — to track symptom change objectively.
These measures give us data that complements your subjective experience. Sometimes patients notice subjective improvement before it shows up clearly in functional terms; sometimes function improves before mood. Validated measures capture multiple dimensions of change and allow us to make evidence-based decisions about your treatment plan.
We also discuss your experience at each session — not just as a check-in, but as part of the clinical picture. How is sleep? Energy? Motivation? Are there domains of function that are improving that others are not? These conversations shape the ongoing care plan.
Same-week consultation appointments are available. Call (430) 288-5800 or use the Schedule button to get started.
This page is educational and is not a substitute for personalized medical advice.
Bottom Line
SPRAVATO® can produce antidepressant effects faster than traditional medications — some patients notice changes within days, most by the end of the 4-week induction. East Texas Psychiatry tracks your progress systematically in Tyler, TX. Call (430) 288-5800.
We accept Medicare, Aetna, Blue Cross Blue Shield, Cigna/Evernorth, Optum, UHC, UMR, and Ambetter. Prior authorization managed by our team — you focus on care. Call (430) 288-5800 or schedule online.
We accept Medicare, Aetna, Blue Cross Blue Shield, Cigna/Evernorth, Optum, UnitedHealthcare, UMR, and Ambetter. Our team handles prior authorization — you focus on care. Visit us at 100 Independence Pl, Suite 405, Tyler, TX 75703, or call (430) 288-5800 or schedule online.
LocationFind Us in Tyler, TX
East Texas Psychiatry and Counseling serves Tyler and the surrounding East Texas region from our clinic at 100 Independence Pl, Suite 405, Tyler, TX 75703. Secure telepsychiatry is available for patients anywhere in Texas — same provider, same thoroughness, from wherever you are.
To schedule a new patient evaluation or ask about your insurance benefits, call (430) 288-5800 or submit a request online. Our intake team verifies your coverage before your first visit so there are no surprises. We accept Medicare, Aetna, Blue Cross Blue Shield, Cigna/Evernorth, Optum, UHC, UMR, and Ambetter, and self-pay options are available.
Whether your concern is treatment-resistant depression, anxiety, ADHD, or another psychiatric condition, we offer a 90-minute initial evaluation and a plan built collaboratively — not handed to you. Most new patients are seen within a week.
How We Reviewed This Page
This page was written for East Texas Psychiatry and Counseling and reviewed by our board-certified psychiatric-mental health nurse practitioners for clinical accuracy. It draws on guidance from primary sources such as the National Institute of Mental Health and other .gov/.org authorities cited below, and reflects how our Tyler-based team approaches care. It is reviewed and updated regularly. East Texas Psychiatry and Counseling is committed to transparent, evidence-based psychiatric care for adults throughout Tyler and East Texas, delivered with the time and attention every patient deserves.
What’s new: June 2026 — full content review and brand-aligned rebuild.
References & Trusted Resources
- National Institute of Mental Health — Health Topics. https://www.nimh.nih.gov/health/topics
- 988 Suicide & Crisis Lifeline. https://988lifeline.org/
- SAMHSA National Helpline. https://www.samhsa.gov/find-help/national-helpline
